请使用支持JavaScript的浏览器! CellGenix/CellGenix® rh IL-4/50µg/1403-050_蚂蚁淘,【正品极速】生物医学科研用品轻松购|ebiomall 蚂蚁淘商城
商品信息
联系客服
CellGenix/CellGenix® rh IL-4/50µg/1403-050
郑重提醒:
无质量问题不接受退换货,下单前请仔细核对信息。
下单后请及时联系客服核对商品价格,订单生效后再付款。
CellGenix/CellGenix® rh IL-4/50µg/1403-050
品牌 / 
CellGenix
货号 / 
1403-050
美元价:
(友情提示:该价格仅为参考,欢迎联系客服询价!)
数    量:
免费咨询热线
4000-520-616

Technical Details

Source
Expressed in E. coli
Description

Human Interleukin-4, accession # P05112, His25-Ser153

Formulation

Lyophilized from a 0.2 µm-filtered solution containing 1.5 mM potassium phosphate, 8.1 mM sodium phosphate, 2.7 mM potassium chloride and 137 mM sodium chloride, pH 7.5

Both product grades are produced under the same conditions in a GMP facility, ensuring an equal product quality and performance. We offer a more comprehensive QC testing including tighter specifications and documentation for our GMP products: Preclinical vs GMP.

 PreclinicalGMP
Molecular weight15.1 kDa15.1 kDa
Purity≥ 95% as determined by SDS-PAGE≥ 97% as determined by SDS-PAGE
Activity≥ 6 x 106 IU/mg, calibrated against NIBSC #88/656 Measured in a cell proliferation assay using an IL-4-dependent cell line, TF18 – 14 x 106 IU/mg, calibrated against NIBSC #88/656 Measured in a cell proliferation assay using an IL-4-dependent cell line, TF1

Batch specific activity on CoA

Endotoxin level< 1000 EU/mg≤ 50 EU/mg
Intended useIntended for preclinical ex vivo use. Not intended for therapeutic use.Intended for clinical ex vivo use. Not intended for human in vivo application.

Handling Instructions

Reconstitution

Recommended in sterile water to a final concentration of 250 µg/ml for 50 µg vials or 500 µg/ml for 1 mg vials.

Shipment

Ambient temperature. Please refer to Technote to learn more about our shipment validation procedure.

Expiry

≥ 6 months from date of shipping. Please refer to Certificate of Analysis for the exact expiry date.

Storage & Stability

Store lyophilized cytokine at -20°C to -80°C.

Store a 250 µg/ml reconstituted cytokine solution:

• 4 weeks at 2°C to 8°C under sterile conditions after reconstitution. Store in the original container. 

• 4 months at -20°C to -80°C under sterile conditions after reconstitution. Store in 60 µl aliquots in polypropylene cryogenic vials.

Avoid repeated freeze/thaw cycles.

Documents

  • Data Sheet: GMP or Preclinical
  • Material Safety Data Sheet: MSDS
  • Certificate of Analysis
  • Technote: ADCF and Serum-free Policy
  • Technote: Batch-to-Batch Consistency of CellGenix® GMP Cytokines
  • Technote: Stability of CellGenix® GMP Cytokines after Reconstitution
  • Technote: Shipment of CellGenix® Preclinical and GMP Cytokines at Ambient Temperatures
  • Technote: CellGenix® rh Cytokines - Preclinical vs GMP
  • More information under Resources

Data

CellGenix GMP rh IL-4 has an activity of 8 – 14 × 106 IU/mg

The activity of GMP rh IL-4 was measured in a cell proliferation assay using the IL-4-dependent cell line TF1. It was calibrated against NIBSC #88/656.

You can find the batch specific activity on the certificate of analysis (CoA).

Regulatory Support

We offer the following to assist you with your regulatory approval process:

  • Comprehensive documentation (e.g. DMFs, Regulatory Support Files, Certificates of Origin)
  • Outstanding QC support (e.g. extensive stability data)
  • The possibility to audit our production site
  • Detailed batch specific test results on our Certificates of Analysis
  • Change notifications prior to relevant changes

Customized solutions can be provided to meet special compliance needs. Contact our Regulatory Support Team for all your regulatory requests & questions:

Phone:     +49 761 88 88 9-302 Email:      regulatorysupport@cellgenix.com

In order to stay up-to-date and help improve regulatory guidance we are actively involved in many of the regulatory initiatives and discussions. We were amongst others actively involved in the discussions for the setup of Ph. Eur. General Chapter 5.2.12 and the ISO Technical Standard 20399.

Regulatory Resources

  • TSE certificate (available on request)
  • Regulatory Support File (available on request)
  • Request a DMF Letter of Authorization (USA only)

Publications

  • The importance of material selection in the differentiation of monocytes into dendritic cellsBoghosian et al., 2018, Cell & Gene Therapy Insights
  • Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritisBell, GM. Et al., 2017, Annals of the Rheumatic Diseases
  • Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21Hansen, M. et al., 2016, Cytotherapy
  • Tumor antigen–specific T cells for immune monitoring of dendritic cell–treated glioblastoma patientsMüller, I. et al., 2016, Cytotherapy
  • Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate CancerXi, HB. et al., 2015, Biological & Pharmaceutical Bulletin
  • Necrotic cell-derived high mobility group box 1 attracts antigen-presenting cells but inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem cells for apoptotic cell deathVogel, S. et al., 2015, Cell Death and Differentiation
  • NF-kB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environmentDá?ová, K. et al., 2015, Oncotarget
  • Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantationSundarasetty, BS. et al., 2015, Journal of Translational Medicine
  • Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patientsGao, D. et al., 2014, PLoS One
  • A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanomaPoschke, I. et al., 2014, Cancer Immunology, Immunotherapy
  • Antigen-specific activation and cytokine-faciliated expansion of naive, human CD8+ T cellsWölfl, M., Greenberg, PD., 2014, Nature Protocols
  • TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIFKolanowski, ST. et al., 2014, Innate Immunity
  • Inhibition of TNF receptor signaling by anti-TNF-a biologicals primes naive CD4+ T cells towards IL-10+ T cells with a regulatory phenotype and functionBooks, MA. et al., 2014, Clinical Immunology
  • In-chip fabrication of free-form 3D constructs for directed cell migration analysisOlsen, MH. et al., 2013, Lab on a Chip
  • The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysatesPellegatta, S. et al., 2013, Oncoimmunology
  • Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapyHansen, M. et al., 2013, Vaccine
  • Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancerIclozan, C. et al., 2013, Cancer Immunology, Immunotherapy
  • Melanoma immunotherapy using mature DCs expressing the constitutive proteasomeDanull, J. et al., 2013, The Journal of Clinical Investigation
  • Crosstalk between Toll like receptors and C5a receptor in human monocyte derived DCs suppress inflammatory cytokine produtionZaal, A. et al., 2013, Immunobiology
  • Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patientsRidolfi, L. et al., 2013, Journal of Translational Medicine
  • The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cellsSorvillo, N. et al., 2012, Blood
  • Myeloid-derived suppressor cells impair the quality of dendritic cell vaccinesPoschke, I. et al., 2012, Cancer Immunology, Immunotherapy
  • Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A miceWroblewska, A. et al., 2012, Blood
  • Is Anticancer Vaccine Possible: Experimental Application of Produced mRNA Transfected Dendritic Cells Derived from Enriched CD34+ Blood Progenitor CellsLazarova, P. et al., 2012, Immunodeficiency, Chapter 3
  • Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapyVopenkova, K. et al., 2012, Journal of Cellular and Molecular Medicine
  • Identitiy, potency in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapyPincha, M. et al., 2012, Human Gene Therapy Methods
  • An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastomaNava, S. et al., 2012, PloS One
  • A phase II study evaluating the safety and efficacy of an adenovirus-DLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinomaChia, WK. et al., 2012, Annals of Oncology
  • Cryopreservation of adenovirus-transfected dendritic cells (DCs) for clinical useGülen, D. et al., 2012, International Immunopharmacology
  • IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction – a comparative study of human clinical-applicable DCBoks, MA. et al., 2012, Clinical Immunology
  • HLA-DR-presented peptide-repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIIIvan Haren, SD. et al., 2011, Molecular & Cellular Proteomics
  • Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitroEtminan, N. et al., 2011, British Journal of Cancer
  • Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolizationNakamato, Y. et al., 2011, Clinical and Experimental Immunology
  • Antigen-Specific B Cells Reactivate an Effective Cytotoxic T Cell Response against Phagocytosed Salmonella through Cross-Presentationde Wit, J. et al., 2010, PLoS One
  • Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcomeVenanzi, FM. et al., 2010, Cancer, Immunology, Immunotherapy
  • A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oyaliplatin/capecitabine chemotherapy in colon cancer patientsLesterhuis, WJ. et al., 2010, British Journal of Cancer
  • Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis)Ridolfi, L. et al., 2010, Clinical and Developmental Immunology
  • Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cellsTraxlmayr, MW. et al., 2010, Journal of Immunotherapy
  • Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patientsLesterhuis, WJ. et al., 2010, Anticancer Research
  • Dendritic cell-based vaccination of patients with advanced melanoma: update of clinical outcomeRidolfi, L. et al., 2010, Clinical and Developmental Immunology
  • Autologous dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteersLuo, J. et al., 2010, Vaccine
  • Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trialTrepiakas, R. et al., 2010, Cytotherapy
  • CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signalsSender, LY. et al., 2010, Molecular Immunology
  • Monophosphoryl lipid A plus IFN gamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic cells with high cytolytic potentialten Brinke, A. et al., 2010, Cancer Immunology, Immunotherapy
  • Development of a potency assay for human dendritic cells: IL-12p70 productionButterfield, LH. et al., 2008, Journal of Immunotherapy
蚂蚁淘电商平台
ebiomall.com
公司介绍
公司简介
蚂蚁淘(www.ebiomall.cn)是中国大陆目前唯一的生物医疗科研用品B2B跨境交易平台, 该平台由多位经验丰富的生物人和IT人负责运营。蚂蚁淘B2B模式是指客户有采购意向后在蚂蚁 淘搜索全球供应信息,找到合适的产品后在蚂蚁淘下单,然后蚂蚁淘的海外买手进行跨境采购、 运输到中国口岸,最后由蚂蚁淘国内团队报关运输给客户...
蚂蚁淘承诺
正品保证: 全球直采 在线追溯 蚂蚁淘所有产品都是自运营的,我们已经跟国外多家厂方建立品牌推广合作关系, 获得对方的支持和授权; 同时客户可以通过订单详情查看到货物从厂方至客户的所有流程, 确保货物的来源; 正规报关,提供13%增值税发票。
及时交付: 限时必达 畅选无忧 蚂蚁淘的运营团队都是有着多年经验的成员,他们熟悉海外采购、仓储物流、报关等环节; 同时通过在线的流程监控,蚂蚁淘的进口速度比传统企业提高了50%以上, 部分产品甚至能做到7-10天到货,即蚂蚁淘的“时必达”服务。
轻松采购: 在线下单 简单省事 蚂蚁淘的价格是真实透明的,并且具有很大的价格优势,不需要繁杂的询价比价; 报价单与合同可以直接在线生成或打印;就像在京东购物一样, 您的鼠标点击几 次即完成在蚂蚁淘的采购,订单详情会告诉您所有进程。
售后申请: 耐心讲解 优质服务 蚂蚁淘提供的产品在使用过程中如因产品质量问题有售后需求时, 您可通过我的订单提交您的“申请售后”, 蚂蚁淘产品顾问会第一时间为您处理, 在售后服务过程中如遇到问题也可致电蚂蚁淘客服热线:4000-520-616。
CHXXS 15:19:15您好李果 15:19:34您好CHXXS 15:19:41我想问一下,您那边有没有表达Her2的肿瘤细胞株李果 15:19:50稍等李果 15:47:48SK-BR-3 [SKBR3]细胞是由Trempe·G和Old·L·J于1970年从一位43岁的白人女性乳腺癌患者的胸腔积液中分离得到的。SK-BR-3 [SKBR3]细胞亚显微结构特征包括微丝和桥粒、肝糖原颗粒、大溶酶体、成束的细胞质纤丝;SK-BR-3 查看更多>
Acris abcam cst Biorbyt santa Novus sigma lifespan NEB roche ABI R&D milliporeBD Qiagen Cayman Jackson Life GeneTexBio-Rad DSHB tocrispeprotech 等品牌;部分产品现货,超低比价,另常备 Trizol DMSO lipo2000lipo3000 SC-2004 SC-2005常备现货 ;货期 查看更多>
巨噬细胞的分离1)从小鼠、豚鼠或家兔腹腔中分离巨噬细胞1.取6周左右的小鼠(或600克左右的豚鼠,或3公斤左右的家兔),剃去腹部的毛并消毒。腹腔注射1ml(豚鼠20ml,家兔200ml)无菌的液体石蜡或巯基乙酸肉汤或4%淀粉肉汤。3~4天以后收集腹腔细胞。2.如要收集腹腔静置巨噬细胞,不注射刺激物 查看更多>
江阴齐氏生物科技有限公司 公司地址:江苏省江阴市国家高新区东盛西路6号A7-1栋 邮政编码:214437 传 真:0510-86419769 销售中心 固定电话:0510-86419770、0510- 86419771、0510-86419772 24小时销售热线:133... 查看更多>
本文由赵勇江整理转载自微信公众号:郑大一附院遗传与产前诊断中心感谢:赵军红、江淼、鲁宁、李姝芳对于本文的审核。临床工作中遇到可能遗传相关问题,如复发性流产、胎儿畸形史等,会建议病人进行染色体检查,可是染色体的检查报告,你能正确解读吗?下面一起来看一下郑大一附院遗传与产前诊断中心赵勇江医生为大家整理的染色体报告解读方面的内容,相信看 查看更多>
细胞复苏和培养手册(请收藏) 查看更多>
默瑞(上海)生物科技有限公司在发布的AddexBio细胞株LN-319 cells供应信息,浏览与AddexBio细胞株LN-319 cells相关的产品或在搜索更多与AddexBio细胞株LN-319 cells相关的内容。 查看更多>
关键词:ES-D3(CRL-1934) ES-D3(CRL-1934)细胞 细胞株产品简介:我公司主要经营ELISA试剂盒、细胞、抗体、生物试剂、耗材、培养基、一抗、二抗、其产品吸附均匀,吸附性好,空白值低,孔底透明度高,代做ELISA实验,全国范围内免费快递运输,如出现运输质量问题,我们可以包退换货。请放心购买产品详情:ES-D3(CRL-1934) ES-D3(CRL-1934)细胞 细胞株规格:96T/48T保存条件:2-8℃厂商 查看更多>
韩宝惠教授 个体化治疗是近年来肺癌治疗的发展方向,每年都有大量新的研究成果问世, 第三届中国肺癌个体化治疗大会于 2013 年 3 月 16 日举行。会议期间,丁香园专访了上海交通大学附属胸科医院肺内科主任韩宝惠教授。 丁香园:韩教授,您好,感谢您接受丁香园的采访!本次大会您做了小细胞肺癌治疗策略的主题报告,其中提到小细胞肺癌近 30 年来的治疗并没有突 查看更多>
关键词:LS 180(CL-187) LS 180(CL-187)细胞 细胞株产品简介:我公司主要经营ELISA试剂盒、细胞、抗体、生物试剂、耗材、培养基、一抗、二抗、其产品吸附均匀,吸附性好,空白值低,孔底透明度高,代做ELISA实验,全国范围内免费快递运输,如出现运输质量问题,我们可以包退换货。请放心购买产品详情:LS 180(CL-187) LS 180(CL-187)细胞 细胞株规格:96T/48T保存条件:2-8℃厂商:上海通 查看更多>
美国EnCor Biotechnology Inc品牌产品目录/代理商价格 查看更多>
常见问题
蚂蚁淘所售产品均为正品吗?
蚂蚁淘的创始人兼CEO是钟定松先生,具有十年的从业经验,在业界享有良好的口碑; Ebiomall是跨境直采平台,我们直接从厂家采购,自己的团队负责国际物流和清关,中间没有第三方,蚂蚁淘承诺所售产品仅为正品,假一罚十。
下单后可以修改订单吗?
未确认状态的订单可以修改,打开“订单详情”页面,点击右上角的“修改订单”即可,若已审核确定,则订单无法修改。
商品几天可以发货?
现货产品付款审核后即可发货,大部分期货产品在3周左右即可到货,提供时必达服务的产品订单审核十天内即可发货。
订单如何取消?
如订单处于未确定状态,进入“我的订单"页面,找到要取消的订单,点击“取消订单”按钮。
可以开发票吗?
本网站所售商品都是正规清关,均开具13%正规发票,发票金额含配送费金额,另有说明的除外。
如何联系商家?
蚂蚁淘任何页面都有在线咨询功能,点击“联系客服”、“咨询”或“在线咨询”按钮,均可咨询蚂蚁淘在线客服人员, 或拨打4000-520-616,除此之外客户可在 联系我们页面找到更多的联系方式。
收到的商品少了/发错了怎么办?
同个订单购买多个商品可能会分为一个以上包裹发出,可能不会同时送达,建议查看订单详情是否是部分发货状态;如未收到,可联系在线客服或者致电4000-520-616。
退换货/维修需要多长时间?
一般情况下,退货处理周期为客户收到产品一个月内(以快递公司显示签收时间为准),包装规格、数量、品种不符,外观毁损、短缺或缺陷,请在收到货24小时内申请退换货;特殊商品以合同条款为准。
商品咨询
请问肺癌细胞HCC827怎样吹打才能完全吹打开?谢谢!
小弟,近期开始培养乳腺癌细胞,导师让了解一下咯细胞株的特性,在网上百度了一下,找不全。MDA-MB-231,MDA-MB-468,MDA-MB-435,SKBR3,MCF-7......只百度出MCF-7是ER(+),PR(+),Her-2(-)
希望有大神赐教!谢谢!
正常的尿液中有很少的上皮细胞,来自脱落的输尿管,膀胱,尿道的上皮上,一般在尿检中,这个数值没有太大意义.但是如果这个数值特别高的时候,就要考虑是否有局部炎症或者肿瘤侵袭引起的上皮细胞脱落.但是诊断炎症或者肿瘤时不能单独依赖一项尿检结果.如果没有全身其它症状或者临床指标时,诊断还是不成立的.同时,女性有自己的特殊生理结构:尿道和阴道距离特别近.正是因为两者挨得比较近,所以阴道分泌物很容易混入尿液中.而阴道分泌物大部分都是上皮细胞(阴道上皮脱落的很多).所以,在得到解雇后,要回顾一下自己的分泌物有没有混入尿液中.
指导意见:
毕竟阴道上皮是鳞状上皮,而输尿管,膀胱,尿道的上皮是柱状上皮,形态上是不一样的.所以您要是对您的结果出怀疑态度,首先:重新留尿,做一个复检(留尿时注意防止阴道分泌物污染);或者让值班医生分析一下是那种类型的上皮(鳞状还是柱状).所以不要担心这个结果.一般情况下污染的比较多.
我养的乳腺癌细胞株SKBR3状态不佳,细胞内含大量粗大颗粒,急死了。重新复苏细胞,结果全军覆灭。几十只都无法复苏成功。着急死了。故在此请教各位老师关于该细胞的冻存方法,是不是有什么特别的?我的冻存方法如下:常规消化离心细胞。冻存液即配即用:培养基:FBS:DMSO=7:2:1。4度放30分钟,-20度2小时,然后放到-80度。我养的另一只乳腺癌细胞MCF-7在此条件下可以成功复苏。复苏时温度38度左右,摇1分钟左右。请问我需要怎么改进?谢谢!如果您有养这株细胞的经验,请指教一二,包括我目前情况的处理方法,谢谢!
患者信息:女24岁江苏南京
病情描述(发病时间、主要症状等):
体检血常规中血小板计数343.血小板比积0.39.
尿检中白细胞计数26.2.上皮细胞计数10.30
心电图下写窦性心律,p-r间期偏短

想得到怎样的帮助:
有没有什么大问题

如题,求助。做肝癌细胞侵袭、迁移实验,用哪种细胞株比较好?

阴道分泌物带来的
相关疾病:卵巢癌各位大大:本人需要作卵巢癌细胞株ovcar-3的培养,有哪位前辈有做过这方面工作的能否指导一下,有没...
我买了一管ATCC细胞株。是不是最好大量培养,然后冻存,分次取用于实验?但以前没买过,不知道“一管”第一次要用多少培养基培养呢?
请教处理步骤。
您好,尿常规中上皮细胞有4-7个是比较高的,一般是有尿道炎的可能性比较大,建议最好积极治疗,不要延误最佳治疗时间啊!
化验单英文缩写 123
meng83182017-10-02
1:白细胞计数(WBC)(参考值:4~10),(单位:10^9/L)  
  2:红细胞计数(RBC)(参考值:3.5~5.5),(单位:10^12/L)  
  3:血红蛋白浓度(HB)(参考值:120~160),(单位:g/L)
  4:红细胞压积(HCT)(参考值:40~48),(单位:%)  
  5:平均红细胞体积(MCV)(参考值:80~97),(单位:fL)  
  6:平均红细胞血红蛋白含量(MCH)(参考值:26.5~33.5),(单位:pg)
  7:平均红细胞血红蛋白浓度(MCHC)(参考值:300~360),(单位:g/L)  
  8:血小板计数(PLT)(参考值:100~300),(单位:10^9/L)  
  9:淋巴细胞比值(LY%)(参考值:17~48),(单位:%)  
  10:单核细胞比例(MONO%)(参考值:4-10),(单位:%)  
  11:中性粒细胞比例(NEUT%)(参考值:43~76),(单位:%)  
  12:淋巴细胞计数(LY)(参考值:0.8~4.0),(单位: 10^9/L)   
  13:单核细胞计数(MONO)(参考值:0.3~0.8),(单位:10^9/L)
  14:中性粒细胞计数(NEUT)(参考值:1.2~6.8),(单位:10^9/L)  
  15:红细胞分布宽度(参考值:11~14.5),(单位:%)  
  16:血小板体积分布宽度(PDW)(参考值:9~18),(单位:%)
  17:平均血小板体积(MPV)(参考值:7.4~12.5),(单位:fL)
  18:大血小板比例(P-LCR)(参考值:10~50),(单位:%)